Athanatos D, Pados G, Venetis C A, Stamatopoulos P, Rousso D, Tsolakidis D, Stamatopoulos C P, Tarlatzis B C
Clin Exp Obstet Gynecol. 2015;42(3):347-51.
To compare the efficacy and safety of two different second-generation ablation devices, Novasure impedance control system and microwave endometrial ablation (MEA), in cases of abnormal uterine bleeding (AUB).
This is a randomized controlled trial that took place in a single Gynecological Department of a University Hospital. Sixty-six women with dysfunctional uterine bleeding (DUB), unresponsive to medical treatment, were included in the trial. The ratio of women allocated to bipolar radio-frequency ablation or MEA was 1:1. Follow-up assessments were carried out at three and 12 months post-ablation. The present main outcome measure was amenorrhea rates 12-months post-treatment.
The rate of amenorrhea at 12-months post-ablation was significantly higher in women treated by Novasure (25/33; 75.8%) as compared to those treated by MEA (8/33; 24.2%) (rate difference: +51.5%, 95% CI: +27.8 to +67.7).
In women with DUB, endometrial ablation with Novasure bipolar radiofrequency impedance-controlled system is associated with increased rates of amenorrhea at 12-months post-treatment as compared to the MEA method.
比较两种不同的第二代消融设备——Novasure阻抗控制系统和微波子宫内膜消融术(MEA)——在异常子宫出血(AUB)病例中的疗效和安全性。
这是一项在大学医院单一妇科进行的随机对照试验。66例对药物治疗无反应的功能失调性子宫出血(DUB)女性被纳入试验。分配接受双极射频消融或MEA治疗的女性比例为1:1。在消融后3个月和12个月进行随访评估。目前的主要结局指标是治疗后12个月的闭经率。
与接受MEA治疗的女性(8/33;24.2%)相比,接受Novasure治疗的女性在消融后12个月的闭经率显著更高(25/33;75.8%)(率差:+51.5%,95%CI:+27.8至+67.7)。
在患有DUB的女性中,与MEA方法相比,采用Novasure双极射频阻抗控制系统进行子宫内膜消融与治疗后12个月闭经率增加相关。